Institut Gustave Roussy, Villejuif, France
M. Ducreux , P. Rougier , D. Smith , C. N. J. Focan , P. F. Innominato , M. Bouchahda , Y. Ajavon , D. Castaing , T. De Baere , A. Karaboué , C. Lepere , V. Boige , R. Adam , F. Levi
Background: HAI of chronomodulated irinotecan (I), 5-Fluorouracil (F) and oxaliplatin (O) (chronoIFO) as well as HAI of O combined with iv F and leucovorin allowed complete macroscopic resections of CRC liver metastases in patients with prior failure on systemic chemotherapy (Bouchahda, Cancer 2009; Goere, Ann Surg 2010). Purpose: To evaluate the resection rate of CRC liver metastases through combining HAI of IFO with cetuximab (Cet) in the first prospective European trial (Lévi, ASCO 2010, TPS#198). Methods: Patients with wt KRAS CRC and unresectable liver metastases receive iv Cet (500 mg/m2, D 1 10:00-12:30) and chrono or conventional HAI of I (180 mg/m2 D1), F (2800 mg/m2/d D2-D3/4), and O (85 mg/m2 D2-3/4) q2 weeks. Grade 3-4 toxicities were managed with dose adaptation and/or supportive measures. Results: 23 patients (9F, 14 M; 33-76 y; PS 0-1) completed full assessment. They had bilateral liver lesions (82%), a median of 7 metastases [2-30; largest diameter, 38 mm (11-150)] and received ≥2 prior iv chemotherapy lines (61%). A median of 4 protocol courses (1-12) was given. Main grade 3-4 toxicities per patient were neutropenia (39%), abdominal pain (30%), fatigue (22%), and leukopenia (17%). An objective tumor response was achieved in 10/23 patients (43.4%). Seven patients underwent liver surgery (30.4%). 17 pts are alive with a median follow up of 16 months. One responding patient with 25 metastases measuring up to 6 cm and involving all liver segments had pathologic complete response in 24 of 25 lesions removed through three-stage hepatectomy. Conclusions: OPTILIV offers a safe and unusually effective treatment option. The trial aims at accruing 48 eligible patients to provide a statistical estimate of the complete macroscopic resection rate and survival in patients with liver metastases from refractory colorectal cancer receiving intravenous cetuximab and hepatic artery infusion of triplet chemotherapy.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Takako Yoshii
2012 ASCO Annual Meeting
First Author: Francis Levi
First Author: Mohamed Bouchahda
First Author: Rui Liu